Literature DB >> 34114629

Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.

Craig Erker1, Adam Lane2, Brooklyn Chaney3, Sarah Leary4, Jane E Minturn5, Ute Bartels6, Roger J Packer7, Kathleen Dorris8, Nicholas G Gottardo9,10, Katherine E Warren11, Alberto Broniscer12,13, Mark W Kieran14, Xiaoting Zhu15,16,17, Peter White18, Phillip J Dexheimer18, Katie Black3, Anthony Asher3, Mariko DeWire3, Jordan R Hansford19, Sridharan Gururangan20, Javad Nazarian21,22, David S Ziegler23,24, Eric Sandler25, Allison Bartlett3, Stewart Goldman26, Chie-Schin Shih27, Tim Hassall28, Hetal Dholaria29, Pratiti Bandopadhayay11, Yvan Samson30, Michelle Monje31, Paul G Fisher31, Andrew Dodgshun32, Sarah Parkin32, Murali Chintagumpala33, Karen Tsui34, David Gass35, Valerie Larouche36, Emmett Broxson37, Mercedes Garcia Lombardi38, Stacie Shiqi Wang19, Jie Ma39, Cynthia Hawkins40, Dima Hamideh41, Lars Wagner42, Carl Koschmann43, Christine Fuller44, Rachid Drissi45,46, Blaise V Jones47, James Leach47, Maryam Fouladi46,48.   

Abstract

BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can occur in adolescents and young adults. The purpose of this study was to describe clinical, radiological, pathologic, and molecular characteristics in patients ≥10 years of age with DIPG enrolled in the International DIPG Registry (IDIPGR).
METHODS: Patients ≥10 years of age at diagnosis enrolled in the IDIPGR with imaging confirmed DIPG diagnosis were included. The primary outcome was overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term survivors (STS) (<24 months).
RESULTS: Among 1010 patients, 208 (21%) were ≥10 years of age at diagnosis; 152 were eligible with a median age of 12 years (range 10-26.8). Median OS was 13 (2-82) months. The 1-, 3-, and 5-year OS was 59.2%, 5.3%, and 3.3%, respectively. The 18/152 (11.8%) LTS were more likely to be older (P < .01) and present with longer symptom duration (P < .01). Biopsy and/or autopsy were performed in 50 (33%) patients; 77%, 61%, 33%, and 6% of patients tested had H3K27M (H3F3A or HIST1H3B), TP53, ATRX, and ACVR1 mutations/genome alterations, respectively. Two of 18 patients with IDH1 testing were IDH1-mutant and 1 was a LTS. The presence or absence of H3 alterations did not affect survival.
CONCLUSION: Patients ≥10 years old with DIPG have a median survival of 13 months. LTS present with longer symptom duration and are likely to be older at presentation compared to STS. ATRX mutation rates were higher in this population than the general DIPG population.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DIPG; International DIPG Registry; outcomes; ≥10 years old

Mesh:

Year:  2022        PMID: 34114629      PMCID: PMC8730773          DOI: 10.1093/neuonc/noab140

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  25 in total

Review 1.  Diffuse brainstem glioma in children: critical review of clinical trials.

Authors:  Darren Hargrave; Ute Bartels; Eric Bouffet
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

Review 2.  Advances toward an understanding of brainstem gliomas.

Authors:  Sarah S Donaldson; Fred Laningham; Paul Graham Fisher
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

3.  Molecular analysis of diffuse intrinsic brainstem gliomas in adults.

Authors:  German Reyes-Botero; Marine Giry; Karima Mokhtari; Marianne Labussière; Ahmed Idbaih; Jean-Yves Delattre; Florence Laigle-Donadey; Marc Sanson
Journal:  J Neurooncol       Date:  2013-11-17       Impact factor: 4.130

4.  Diffuse intrinsic pontine glioma: poised for progress.

Authors:  Katherine E Warren
Journal:  Front Oncol       Date:  2012-12-28       Impact factor: 6.244

5.  Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).

Authors:  S Bailey; A Howman; K Wheatley; D Wherton; N Boota; B Pizer; D Fisher; P Kearns; S Picton; F Saran; M Gibson; A Glaser; D J A Connolly; D Hargrave
Journal:  Eur J Cancer       Date:  2013-09-04       Impact factor: 9.162

6.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.

Authors:  David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily
Journal:  Acta Neuropathol       Date:  2015-09-23       Impact factor: 17.088

Review 7.  Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis.

Authors:  Hadeel Hassan; Anne Pinches; Susan V Picton; Robert S Phillips
Journal:  J Neurooncol       Date:  2017-07-05       Impact factor: 4.130

8.  Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.

Authors:  Lindsey M Hoffman; Sophie E M Veldhuijzen van Zanten; Niclas Colditz; Joshua Baugh; Brooklyn Chaney; Marion Hoffmann; Adam Lane; Christine Fuller; Lili Miles; Cynthia Hawkins; Ute Bartels; Eric Bouffet; Stewart Goldman; Sarah Leary; Nicholas K Foreman; Roger Packer; Katherine E Warren; Alberto Broniscer; Mark W Kieran; Jane Minturn; Melanie Comito; Emmett Broxson; Chie-Schin Shih; Soumen Khatua; Murali Chintagumpala; Anne Sophie Carret; Nancy Yanez Escorza; Timothy Hassall; David S Ziegler; Nicholas Gottardo; Hetal Dholaria; Renee Doughman; Martin Benesch; Rachid Drissi; Javad Nazarian; Nada Jabado; Nathalie Boddaert; Pascale Varlet; Géraldine Giraud; David Castel; Stephanie Puget; Chris Jones; Esther Hulleman; Piergiorgio Modena; Marzia Giagnacovo; Manila Antonelli; Torsten Pietsch; Gerrit H Gielen; David T W Jones; Dominik Sturm; Stefan M Pfister; Nicolas U Gerber; Michael A Grotzer; Elke Pfaff; André O von Bueren; Darren Hargrave; Guirish A Solanki; Filip Jadrijevic Cvrlje; Gertjan J L Kaspers; William P Vandertop; Jacques Grill; Simon Bailey; Veronica Biassoni; Maura Massimino; Raphaël Calmon; Esther Sanchez; Brigitte Bison; Monika Warmuth-Metz; James Leach; Blaise Jones; Dannis G van Vuurden; Christof M Kramm; Maryam Fouladi
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

Review 9.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

10.  External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry.

Authors:  Sophie E M Veldhuijzen van Zanten; Adam Lane; Martijn W Heymans; Joshua Baugh; Brooklyn Chaney; Lindsey M Hoffman; Renee Doughman; Marc H A Jansen; Esther Sanchez; William P Vandertop; Gertjan J L Kaspers; Dannis G van Vuurden; Maryam Fouladi; Blaise V Jones; James Leach
Journal:  J Neurooncol       Date:  2017-05-30       Impact factor: 4.130

View more
  3 in total

1.  Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.

Authors:  Daniele De Brasi; Francesca Orlando; Valeria Gaeta; Maria De Liso; Fabio Acquaviva; Luigi Martemucci; Augusto Mastrominico; Maja Di Rocco
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

2.  The current state of glioma data registries.

Authors:  Alexander G Yearley; Julian Bryan Iorgulescu; Ennio Antonio Chiocca; Pier Paolo Peruzzi; Timothy R Smith; David A Reardon; Michael A Mooney
Journal:  Neurooncol Adv       Date:  2022-06-24

3.  Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors.

Authors:  Cameron Crowell; Daddy Mata-Mbemba; Julie Bennett; Kara Matheson; Michael Mackley; Sébastien Perreault; Craig Erker
Journal:  Neurooncol Adv       Date:  2022-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.